Nitric oxide-dependent mechanism of anti-ischemic myocardial protection induced by monophosphoryl lipid A.
Monophosphoryl Lipid A (MLA) is a detoxified derivative of endotoxin and was first derived and purified from bacterial lipopolysaccharide in 1980s. This pharmacological agent has been studied as a vaccine adjunct, anti-septic, or anti-tumor agent by means of its immunomodulatory properties. In addition, MLA is one of the most well documented protective drugs against cardiac ischemia/reperfusion injury in various animal species. Mechanisms involved with the MLA-induced cardioprotection are still not fully understood. A key role for ATP-sensitive potassium channels and inducible nitric oxide synthase (iNOS) has been proposed. This article provides a brief overview on the updated understanding of MLA-induced cardioprotection and focuses on the new evidence and insights that were brought into the field by a number of new publications during 1998-1999. Our recent study in a globally ischemic mouse heart model is particularly highlighted. An obligatory role for nitric oxide (NO) in mediating the delayed cardioprotective effect induced by MLA via induction of iNOS was double-confirmed by using S-methylisothiourea (SMT)--a specific inhibitors of iNOS as well as the iNOS gene knockout mice. A direct association of the MLA-induced infarct size reduction with increased NO production was also demonstrated in this study. Future studies should target on identifying the key type(s) of cytokine and the receptors as well as free radical-activated transcription factors that may be responsible for induction of iNOS and the subsequent anti-ischemic cardioprotection with MLA. Information gathered in the studies on MLA may eventually enhance our understanding in the mechanisms of delayed phase of myocardial preconditioning and its clinical applications.
Division of Cardiology, Medical College of Virginia, Virginia Commonwealth University, Richmond, VA 23298, USA. leixi01@aol.com
L
L
Xi
D000818:Animals; D008050:Lipid A / Q000031:analogs & derivatives / Q000494:pharmacology*; D009203:Myocardial Infarction / Q000517:prevention & control*; D015428:Myocardial Reperfusion Injury / Q000517:prevention & control; D019001:Nitric Oxide Synthase / Q000502:physiology*; D052247:Nitric Oxide Synthase Type II; D015221:Potassium Channels
D008050:Lipid A; D015221:Potassium Channels; D019001:Nitric Oxide Synthase; D052247:Nitric Oxide Synthase Type II; C048436:monophosphoryl lipid A